At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 279 enrolled
Drug / intervention
LevoCeptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Effectiveness, Safety and Tolerability of LevoCept (Levonorgestrel-Releasing Intrauterine System) for Long-Acting Reversible Contraception
In Brief
A Phase 2 clinical trial evaluating LevoCept for Contraception. Completed, enrolled 279 participants across 16 sites.
Detailed Summary
To evaluate the effectiveness, device placement, safety, and tolerability of LevoCept to support commencing a Phase III Clinical Study
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
CountriesUnited States
CollaboratorsSynteract, Inc.
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartNov 2016
Primary CompletionJul 2018
Study CompletionNov 2020
TodayJul 2026
First PostedAug 29, 2016
Enrollment StartNov 1, 2016
Primary CompletionJul 17, 2018
Study CompletionNov 12, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.8 years ago
Interventions
LevoCeptdrug
placement of LevoCept IUD